MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience Jan 14 • 3 min read MindMed announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Novamind Expands Psychedelic Medicine Access in Utah Jan 13 • 2 min read Novamind Inc. announced the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah.
PharmaTher Approved to Trade on the OTCQB Venture Market Jan 13 • 2 min read Newscope Capital Corporation, who through its wholly-owned subsidiary, PharmaTher Inc., announced that its common shares have been approved for trading on the OTCQB® Venture Market effective today.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers Jan 12 • 3 min read MindMed announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance.
Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics Jan 11 • 4 min read Cybin Inc. announced that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel.